<DOC>
	<DOC>NCT01437423</DOC>
	<brief_summary>The purpose of this study is to assess the safety of TETRAXIM™ administered in routine clinical practice according to Korea Food and Drug Administration Notification No. 2009-46 "Basic standard for reexamination of new drug" based on the pharmaceutical law in Korea.</brief_summary>
	<brief_title>Regulatory Post-Marketing Surveillance Study for TETRAXIM™</brief_title>
	<detailed_description>Primary vaccination will be administered from 2 months and booster vaccination from age 4 to 6 years.</detailed_description>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Tetany</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<criteria>Subjects who are 2 months or more of age (as indicated in the currently approved local product labeling) and who are given the study vaccine at least one dose or more, during a routine healthcare visit, as primary immunization or booster immunization for the prevention of diphtheria, tetanus, pertussis, poliomyelitis. Written informed consent obtained from the subject's parents/legal representative.</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Pertussis</keyword>
	<keyword>Poliomyelitis</keyword>
	<keyword>TETRAXIM™</keyword>
</DOC>